Volasertib (also known as BI 6727) is an experimental small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim...
16 KB (1,760 words) - 07:49, 10 June 2024
cancer. Already approved for non-small cell lung cancer (NSCLC) Phase III Volasertib PLK1 antagonist Various cancer types Phase III Deleobuvir (formerly BI...
39 KB (3,271 words) - 11:44, 24 July 2024
were selectively killed, without harming normal cells. PLK1 inhibitor volasertib is being evaluated in clinical trials for use in acute myeloid leukemia...
16 KB (1,929 words) - 07:57, 4 January 2024
Vizimpro Vocabria voclosporin (USAN) Vogelxo voglibose (INN) Vokanamet volasertib (INN, USAN) volazocine (INN) Volibris volinanserin (USAN) Volmax Volnea...
8 KB (430 words) - 05:09, 19 June 2024
J; Adolf, G. R; Kraut, N (2015). "Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical...
10 KB (810 words) - 07:11, 27 February 2023